Drugging DNA repair to target T-ALL cells

Leuk Lymphoma. 2018 Jul;59(7):1746-1749. doi: 10.1080/10428194.2017.1397662. Epub 2017 Nov 8.

Authors

Yashodhara Dasgupta¹, Konstantin Golovine¹, Margaret Nieborowska-Skorska¹, Li Luo², Ksenia Matlawska-Wasowska³, Charles G Mullighan⁴, Tomasz Skorski¹

Affiliations

¹ a Department of Microbiology and Immunology, Fels Institute for Cancer Research & Molecular Biology , Temple University Lewis Katz School of Medicine , Philadelphia , PA , USA.
² b Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine , University of New Mexico , Albuquerque , NM , USA.
³ c Division of Pediatric Research, Department of Pediatrics , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.
⁴ d Department of Pathology , St. Jude Children's Research Hospital , Memphis , TN , USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor
DNA Damage
DNA Repair / drug effects*
Gene Expression Regulation, Neoplastic / drug effects
Humans
Molecular Targeted Therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics*

Substances

Antineoplastic Agents
Biomarkers, Tumor

Grants and funding

R21 CA189378/CA/NCI NIH HHS/United States